NYSE:BMY - Bristol-Myers Squibb Stock Price, Price Target & More

$51.61 -0.69 (-1.32 %)

(As of 04/20/2018 05:06 AM ET)

Previous Close$52.30

Today's Range$51.51 - $52.54

52-Week Range$51.51 - $70.05

Volume17.15 million shs

Average Volume8.57 million shs

Market Capitalization$85.38 billion

P/E Ratio17.38

Dividend Yield3.05%

Beta0.96

About Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a strategic development and commercialization collaboration agreement with Nektar Therapeutics. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNYSE:BMY

CUSIP11012210

Webwww.bms.com

Phone212-546-4000

Debt

Debt-to-Equity Ratio0.59%

Current Ratio1.55%

Quick Ratio1.43%

Price-To-Earnings

Trailing P/E Ratio17.38

Forward P/E Ratio16.03

P/E Growth1.41

Sales & Book Value

Annual Sales$20.78 billion

Price / Sales4.06

Cash Flow$3.4731 per share

Price / Cash14.86

Book Value$7.24 per share

Price / Book7.13

Profitability

EPS (Most Recent Fiscal Year)$3.01

Net Income$1.01 billion

Net Margins4.85%

Return on Equity35.43%

Return on Assets14.85%

Miscellaneous

Employees23,700

Outstanding Shares1,632,580,000

How to Become a New Pot Stock Millionaire

Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb announced a quarterly dividend on Thursday, March 1st. Investors of record on Friday, April 6th will be paid a dividend of $0.40 per share on Tuesday, May 1st. This represents a $1.60 annualized dividend and a yield of 3.10%. The ex-dividend date is Thursday, April 5th. View Bristol-Myers Squibb's Dividend History.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb (NYSE:BMY) released its earnings results on Monday, February, 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.67 by $0.01. The biopharmaceutical company had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The company's quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.63 earnings per share. View Bristol-Myers Squibb's Earnings History.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Bristol-Myers Squibb.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb issued an update on its FY18 earnings guidance on Monday, February, 5th. The company provided earnings per share (EPS) guidance of $3.15-3.30 for the period, compared to the Thomson Reuters consensus estimate of $3.23.

What price target have analysts set for BMY?

20 equities research analysts have issued 12 month target prices for Bristol-Myers Squibb's stock. Their predictions range from $47.00 to $78.00. On average, they anticipate Bristol-Myers Squibb's share price to reach $64.5269 in the next year. View Analyst Ratings for Bristol-Myers Squibb.

What are Wall Street analysts saying about Bristol-Myers Squibb stock?

Here are some recent quotes from research analysts about Bristol-Myers Squibb stock:

1. According to Zacks Investment Research, "Bristol-Myers’ blockbuster drug Opdivo is facing competitive challenges in the United States. With the FDA approving Merck’s Keytruda, for the first-line treatment of metastatic non-squamous NSCLC, the competition will stiffen up. Pricing concerns, stiff competition in the HCV and immuno-oncology space are expected to remain a significant overhang on the company’s shares. Yervoy’s sales are expected to be under pressure due to adoption of Opdivo in adjuvant melanoma. Gross margin is also expected to be under pressure due to product mix and declines in virology business. Shares of the company have underperformed the industry in the last three months. Estimates have remained stable ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters." (1/29/2018)
2. Robert W. Baird analysts commented, "The broader opportunity for 2125, theoretically, is it could be used in many different tumor types and many different cancer indications." (4/25/2017)

Who are some of Bristol-Myers Squibb's key competitors?

Some companies that are related to Bristol-Myers Squibb include Merck & Co. (MRK), AbbVie (ABBV), Novo Nordisk (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Eli Lilly and (LLY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY) and Shiseido (SSDOY).

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the folowing people:

Dr. Giovanni Caforio, Chairman & CEO (Age 53)
Mr. Charles A. Bancroft, CFO & Exec. VP of Global Bus. Operations (Age 58)
Dr. Thomas J. Lynch Jr., Exec. VP of R&D and Chief Scientific Officer (Age 57)
Ms. Sandra Leung, Exec. VP & Gen. Counsel (Age 57)
Mr. Murdo Gordon, Exec. VP & Chief Commercial Officer (Age 51)

Has Bristol-Myers Squibb been receiving favorable news coverage?

Media headlines about BMY stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 0.24 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.98 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $51.61.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $85.51 billion and generates $20.78 billion in revenue each year. The biopharmaceutical company earns $1.01 billion in net income (profit) each year or $3.01 on an earnings per share basis. Bristol-Myers Squibb employs 23,700 workers across the globe.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 345 PARK AVE, NEW YORK NY, 10154. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]

MarketBeat Community Rating for Bristol-Myers Squibb (BMY)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		722 (Vote Outperform)
Underperform Votes:		686 (Vote Underperform)
Total Votes:		1,408

MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Bristol-Myers Squibb (NYSE:BMY) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

20 Wall Street analysts have issued ratings and price targets for Bristol-Myers Squibb in the last 12 months. Their average twelve-month price target is $64.5269, suggesting that the stock has a possible upside of 25.03%. The high price target for BMY is $78.00 and the low price target for BMY is $47.00. There are currently 1 sell rating, 10 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Buy	Hold
Consensus Rating Score:	2.40	2.45	2.50	2.44
Ratings Breakdown:	1 Sell Rating(s) 10 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 9 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 7 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 8 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$64.5269	$67.0894	$65.2308	$63.50
Price Target Upside:	25.03% upside	0.99% upside	4.50% upside	1.06% downside

Bristol-Myers Squibb (NYSE:BMY) Consensus Price Target History

Price Target History for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/18/2018	BMO Capital Markets	Lower Price Target	Underperform -> Underperform	$51.00 -> $47.00	Low
4/17/2018	Credit Suisse Group	Set Price Target	Hold	$58.00	Low
4/17/2018	Bank of America	Lower Price Target	Neutral -> Neutral	$68.00 -> $61.00	Low
4/17/2018	William Blair	Reiterated Rating	Outperform		High
4/17/2018	Morgan Stanley	Downgrade	Overweight -> Equal Weight	$54.08 -> $58.00	High
4/13/2018	Jefferies Group	Reiterated Rating	Hold	$66.00	Low
3/21/2018	Argus	Reiterated Rating	Buy	$75.00 -> $66.43	Low
3/20/2018	JPMorgan Chase	Set Price Target	Overweight -> Overweight	$70.00 -> $75.00	Low
2/28/2018	DZ Bank	Downgrade	Buy -> Hold		High
2/16/2018	Citigroup	Set Price Target	Buy	$78.00	Low
2/6/2018	Leerink Swann	Boost Price Target	Outperform -> Positive	$71.00 -> $76.00	Medium
10/30/2017	SunTrust Banks	Upgrade	Hold -> Buy		N/A
10/27/2017	Piper Jaffray	Reiterated Rating	Hold	$60.00	N/A
10/13/2017	Barclays	Boost Price Target	Equal Weight	$58.00 -> $65.00	N/A
10/6/2017	UBS	Reiterated Rating	Buy	$62.00 -> $72.00	N/A
9/19/2017	Cowen	Reiterated Rating	Hold	$65.00	Low
9/12/2017	Hilliard Lyons	Downgrade	Long-term Buy -> Neutral	$65.00	Low
9/7/2017	Goldman Sachs	Reiterated Rating	Buy	$62.00 -> $65.00	Low
7/17/2017	Deutsche Bank	Set Price Target	Hold	$54.00 -> $55.00	Low
4/25/2017	Robert W. Baird	Initiated Coverage	Outperform		Low
2/9/2017	Gabelli	Reiterated Rating	Buy		N/A
1/8/2017	Evercore ISI	Reiterated Rating	Hold	$55.00	N/A
8/11/2016	Berenberg Bank	Downgrade	Buy -> Hold	$80.00 -> $70.00	N/A
8/11/2016	Sanford C. Bernstein	Reiterated Rating	Market Perform	$79.00 -> $65.00	N/A

(Data available from 4/20/2016 forward)

Bristol-Myers Squibb (NYSE:BMY) Earnings History and Estimates Chart

Earnings by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Earnings Estimates

2018 EPS Consensus Estimate: $3.20
2019 EPS Consensus Estimate: $3.46

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	4	$0.74	$0.85	$0.82
Q2 2018	3	$0.76	$0.82	$0.80
Q3 2018	3	$0.77	$0.82	$0.79
Q4 2018	3	$0.76	$0.84	$0.80
Q1 2019	1	$0.83	$0.83	$0.83
Q2 2019	1	$0.85	$0.85	$0.85
Q3 2019	1	$0.88	$0.88	$0.88
Q4 2019	1	$0.90	$0.90	$0.90

Bristol-Myers Squibb (NYSE BMY) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/26/2018		$0.83					N/A
2/5/2018	Q4 2017	$0.67	$0.68	$5.3479 billion	$5.4490 billion	View	Listen
10/26/2017	Q3 2017	$0.77	$0.75	$5.1957 billion	$5.2540 billion	View	N/A
7/27/2017	Q2 2017	$0.73	$0.74	$5.0876 billion	$5.1440 billion	View	N/A
4/27/2017	Q1 2017	$0.72	$0.84	$4.7485 billion	$4.9290 billion	View	N/A
1/26/2017	Q416	$0.67	$0.63	$5.14 billion	$5.24 billion	View	N/A
10/27/2016	Q316	$0.65	$0.77	$4.76 billion	$4.83 billion	View	Listen
7/28/2016	Q216	$0.67	$0.69	$4.60 billion	$4.90 billion	View	Listen
4/28/2016	Q116	$0.65	$0.74	$4.19 billion	$4.39 billion	View	Listen
1/28/2016	Q415	$0.28	$0.38	$4.07 billion	$4.29 billion	View	Listen
10/27/2015	Q315	$0.35	$0.39	$3.83 billion	$4.07 billion	View	Listen
7/23/2015	Q215	$0.36	$0.53	$3.68 billion	$4.16 billion	View	Listen
4/28/2015	Q115	$0.50	$0.71	$3.80 billion	$4.04 billion	View	N/A
1/27/2015	Q414	$0.40	$0.46	$4.02 billion	$4.26 billion	View	N/A
10/24/2014	Q314	$0.42	$0.45	$3.80 billion	$3.92 billion	View	Listen
7/24/2014	Q214	$0.44	$0.48	$3.85 billion	$3.89 billion	View	Listen
4/29/2014	Q114	$0.43	$0.46	$3.89 billion	$3.81 billion	View	Listen
1/24/2014	Q413	$0.43	$0.53	$4.30 billion	$4.44 billion	View	Listen
10/23/2013	Q313	$0.44	$0.46	$4.02 billion	$4.07 billion	View	Listen
7/25/2013	Q2 2013	$0.45	$0.44	$4.07 billion	$4.05 billion	View	Listen
4/25/2013	Q1 2013	$0.41	$0.41	$3.88 billion	$3.83 billion	View	Listen
1/24/2013	Q4 2012	$0.42	$0.47	$4.14 billion	$4.19 billion	View	Listen
10/24/2012		$0.42	$0.41			View	N/A
7/25/2012		$0.48	$0.48			View	N/A
4/26/2012		$0.64	$0.64			View	N/A
1/26/2012		$0.55	$0.53			View	N/A
10/27/2011		$0.58	$0.61			View	N/A
7/28/2011		$0.55	$0.56			View	N/A
4/28/2011		$0.53	$0.58			View	N/A
1/27/2011		$0.48	$0.47			View	N/A

(Earnings results data provided by Zacks Investment Research)

Bristol-Myers Squibb (NYSE:BMY) Dividend Information

Bristol-Myers Squibb pays an annual dividend of $1.60 per share, with a dividend yield of 3.10%. BMY's next quarterly dividend payment will be made on Tuesday, May 1. The company has grown its dividend for the last 8 consecutive years and is increasing its dividend by an average of 2.70% each year. Bristol-Myers Squibb pays out 53.16% of its earnings out as a dividend.

Next Dividend:	5/1/2018
Annual Dividend:	$1.60
Dividend Yield:	3.10%
Dividend Growth:	2.70% (3 Year Average)
Payout Ratio:	53.16% (Trailing 12 Months of Earnings) 49.69% (Based on This Year's Estimates) 42.78% (Based on Next Year's Estimates)
Track Record:	8 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/1/2018	quarterly	$0.40	2.43568275232151%	4/5/2018	4/6/2018	5/1/2018
12/7/2017	quarterly	$0.40	2.56%	1/4/2018	1/5/2018	2/1/2018
9/13/2017	quarterly	$0.39	2.49%	10/5/2017	10/6/2017	11/1/2017
6/13/2017	quarterly	$0.39	2.86%	7/5/2017	7/7/2017	8/1/2017
3/2/2017	quarterly	$0.39	2.72%	4/5/2017	4/7/2017	5/1/2017
12/8/2016	quarterly	$0.39	2.73%	1/4/2017	1/6/2017	2/1/2017
8/3/2016	quarterly	$0.38	2.02%	10/5/2016	10/7/2016	11/1/2016
6/7/2016	quarterly	$0.38	2.07%	6/29/2016	7/1/2016	8/1/2016
3/3/2016	quarterly	$0.38	2.35%	3/30/2016	4/1/2016	5/2/2016
12/8/2015	quarterly	$0.38	2.22%	12/30/2015	1/4/2016	2/1/2016
9/17/2015	quarterly	$0.37	2.3%	9/30/2015	10/2/2015	11/2/2015
6/16/2015	quarterly	$0.37	2.23%	7/1/2015	7/6/2015	8/3/2015
3/2/2015	quarterly	$0.37	2.39%	4/1/2015	4/6/2015	5/1/2015
12/9/2014	quarterly	$0.37	2.5%	12/30/2014	1/2/2015	2/2/2015
9/16/2014	quarterly	$0.36	2.83%	10/1/2014	10/3/2014	11/3/2014
6/17/2014	quarterly	$0.36	3%	7/1/2014	7/3/2014	8/1/2014
3/3/2014	quarterly	$0.36	2.55%	4/2/2014	4/4/2014	5/1/2014
12/19/2013	quarterly	$0.36	2.7%	12/31/2013	1/3/2014	2/3/2014
9/17/2013	quarterly	$0.35	2.95%	10/2/2013	10/4/2013	11/1/2013
6/19/2013	quarterly	$0.35	3.14%	7/2/2013	7/5/2013	8/1/2013
3/7/2013	quarterly	$0.35	3.74%	4/3/2013	4/5/2013	5/1/2013
12/4/2012	quarterly	$0.35			1/4/2013	2/1/2013

(Data available from 1/1/2013 forward)

Bristol-Myers Squibb (NYSE BMY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 71.51%

Insider Trading History for Bristol-Myers Squibb (NYSE:BMY)

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE BMY) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/15/2017	Theodore R Samuels II	Director	Buy	4,000	$62.30	$249,200.00	22,000
12/12/2017	Thomas J Jr. Lynch	EVP	Sell	5,300	$63.24	$335,172.00	9,251
12/4/2017	Sandra Leung	EVP	Sell	156,582	$63.37	$9,922,601.34	584,373
9/6/2017	Joseph C Caldarella	SVP	Sell	9,340	$60.00	$560,400.00	46,297
8/2/2017	Theodore R Samuels II	Director	Buy	6,000	$55.94	$335,640.00	18,000
4/7/2017	Lamberto Andreotti	Director	Sell	34,000	$53.26	$1,810,840.00	952,571
3/28/2017	Lamberto Andreotti	Director	Sell	34,000	$56.17	$1,909,780.00	986,112
3/27/2017	Lamberto Andreotti	Director	Sell	17,000	$56.14	$954,380.00	986,112
3/17/2017	Louis S Schmukler	Insider	Sell	5,000	$56.49	$282,450.00	21,483
3/15/2017	Joseph C Caldarella	SVP	Sell	8,096	$57.29	$463,819.84	55,637
3/6/2017	Sandra Leung	EVP	Sell	92,405	$57.02	$5,268,933.10	488,063
2/27/2017	Theodore R Samuels II	Director	Buy	12,000	$56.77	$681,240.00	12,000
9/8/2016	Lamberto Andreotti	Director	Sell	21,600	$56.87	$1,228,392.00	334,499
8/25/2016	Lamberto Andreotti	Director	Sell	23,200	$59.17	$1,372,744.00	364,999
7/8/2016	Lamberto Andreotti	Director	Sell	23,200	$74.45	$1,727,240.00	380,099
6/28/2016	Lamberto Andreotti	Director	Sell	23,200	$72.14	$1,673,648.00	403,094
6/14/2016	John E Elicker	SVP	Sell	11,820	$72.69	$859,195.80	55,011
5/20/2016	Charles A Bancroft	CFO	Sell	30,201	$70.79	$2,137,928.79	184,694
5/16/2016	Joseph C Caldarella	SVP	Sell	3,519	$72.47	$255,021.93	55,238
5/6/2016	Sandra Leung	EVP	Sell	72,544	$70.39	$5,106,372.16	444,507
5/5/2016	Lamberto Andreotti	Director	Sell	23,200	$70.54	$1,636,528.00	425,194
5/3/2016	Giovanni Caforio	CEO	Sell	34,594	$71.31	$2,466,898.14	132,263
5/2/2016	Autenried Paul Von	SVP	Sell	37,258	$71.93	$2,679,967.94	128,463
5/2/2016	Lamberto Andreotti	Director	Sell	234,720	$71.88	$16,871,673.60	536,794
5/2/2016	Louis S Schmukler	Insider	Sell	22,218	$71.95	$1,598,585.10	21,971
4/5/2016	Lamberto Andreotti	Director	Sell	23,200	$65.90	$1,528,880.00	453,094
4/4/2016	Lamberto Andreotti	Director	Sell	11,600	$65.79	$763,164.00	453,094
3/9/2016	Lamberto Andreotti	Director	Sell	23,200	$65.71	$1,524,472.00	381,254
3/8/2016	Lewis B Campbell	Director	Sell	2,500	$66.00	$165,000.00	2,500
3/4/2016	Joseph C Caldarella	SVP	Sell	12,962	$64.64	$837,863.68	46,322
2/17/2016	Giovanni Caforio	CEO	Sell	12,040	$63.58	$765,503.20	76,738
2/17/2016	Sandra Leung	EVP	Sell	10,152	$63.57	$645,362.64	309,547
2/12/2016	Lamberto Andreotti	Director	Sell	23,200	$59.61	$1,382,952.00	392,854
1/5/2016	Lamberto Andreotti	Director	Sell	23,200	$67.56	$1,567,392.00	310,424
1/4/2016	Lamberto Andreotti	Director	Sell	11,600	$66.93	$776,388.00	310,424
12/15/2015	Lamberto Andreotti	Director	Sell	23,200	$69.03	$1,601,496.00	332,852
11/20/2015	Lamberto Andreotti	Director	Sell	23,200	$67.39	$1,563,448.00	456,052
10/6/2015	Lamberto Andreotti	Director	Sell	23,200	$60.86	$1,411,952.00	524,252
9/3/2015	Lamberto Andreotti	Director	Sell	23,200	$59.40	$1,378,080.00	546,874
6/4/2015	Joseph C Caldarella	SVP	Sell	16,972	$65.71	$1,115,230.12
3/16/2015	Francis M Cuss	EVP	Sell	114,666	$67.81	$7,775,501.46
3/16/2015	Louis S Schmukler	Insider	Sell	12,000	$66.96	$803,520.00
2/17/2015	Sandra Leung	General Counsel	Sell	11,746	$60.39	$709,340.94
2/12/2015	Samuel J Moed	SVP	Sell	3,880	$59.26	$229,928.80
2/6/2015	Samuel J Moed	SVP	Sell	21,478	$60.15	$1,291,901.70
1/29/2015	Lamberto Andreotti	CEO	Sell	90,246	$61.14	$5,517,640.44
1/29/2015	Lewis B Campbell	Director	Sell	2,500	$60.89	$152,225.00
1/29/2015	Louis S Schmukler	Insider	Sell	5,250	$60.73	$318,832.50
12/5/2014	Lamberto Andreotti	CEO	Sell	75,000	$60.31	$4,523,250.00
10/24/2014	Lamberto Andreotti	CEO	Sell	50,000	$53.00	$2,650,000.00
10/6/2014	Lamberto Andreotti	CEO	Sell	50,000	$50.99	$2,549,500.00
9/16/2014	Francis M Cuss	EVP	Sell	63,667	$50.77	$3,232,373.59
9/15/2014	Giovanni Caforio	COO	Sell	26,691	$49.87	$1,331,080.17
9/10/2014	Joseph C Caldarella	SVP	Sell	7,415	$51.03	$378,387.45
9/8/2014	Lamberto Andreotti	CEO	Sell	50,000	$51.05	$2,552,500.00
8/19/2014	Autenried Paul Von	SVP	Sell	20,000	$49.89	$997,800.00
7/29/2014	Charles A Bancroft	CFO	Sell	67,621	$51.06	$3,452,728.26
7/28/2014	Samuel J Moed	SVP	Sell	25,752	$49.32	$1,270,088.64
3/13/2014	Joseph Caldarella	SVP	Sell	9,137	$55.20	$504,362.40	68,965
3/10/2014	Lamberto Andreotti	CEO	Sell	100,000	$55.52	$5,552,000.00	630,783
3/10/2014	Louis Schmukler	Insider	Sell	8,799	$55.81	$491,072.19	8,861
3/5/2014	James Cornelius	Director	Sell	100,000	$55.82	$5,582,000.00	273,393
2/28/2014	Louis Schmukler	Insider	Sell	6,088	$54.49	$331,735.12	14,696
2/24/2014	Giovanni Caforio	EVP	Sell	41,563	$54.44	$2,262,689.72	49,753
2/19/2014	John Elicker	SVP	Sell	9,534	$54.22	$516,933.48	32,740
2/18/2014	Francis Cuss	EVP	Sell	29,800	$54.61	$1,627,378.00	207,237
2/14/2014	Charles Bancroft	CFO	Sell	52,963	$54.35	$2,878,539.05	77,303
2/14/2014	Sandra Leung	General Counsel	Sell	10,490	$54.28	$569,397.20	195,855
2/11/2014	Lamberto Andreotti	CEO	Sell	86,075	$52.66	$4,532,709.50	500,487
2/6/2014	Joseph Caldarella	SVP	Sell	35,471	$48.90	$1,734,531.90	59,355
2/5/2014	Lewis Campbell	Director	Sell	2,500	$48.28	$120,700.00
2/4/2014	James Cornelius	Director	Sell	100,000	$48.90	$4,890,000.00	373,393
7/29/2013	James M Cornelius	Director	Sell	5,000	$43.81	$219,050.00
6/10/2013	Autenried Paul Von	SVP	Sell	25,000	$47.24	$1,181,000.00
6/6/2013	Joseph C Caldarella	SVP	Sell	26,275	$46.53	$1,222,575.75
6/5/2013	John E Elicker	SVP	Sell	25,997	$46.33	$1,204,441.01
6/4/2013	Lamberto Andreotti	CEO	Sell	100,000	$47.74	$4,774,000.00
6/4/2013	Samuel J Moed	SVP	Sell	58,898	$47.38	$2,790,587.24
6/3/2013	Elliot Sigal	EVP	Sell	83,647	$48.18	$4,030,112.46
5/31/2013	Beatrice J Cazala	EVP	Sell	91,282	$47.00	$4,290,254.00
5/31/2013	Giovanni Caforio	Insider	Sell	10,538	$47.06	$495,918.28
5/30/2013	Beatrice J Cazala	EVP	Sell	22,000	$47.00	$1,034,000.00
5/28/2013	Charles A Bancroft	CFO	Sell	25,000	$48.68	$1,217,000.00
5/28/2013	James M Cornelius	Director	Sell	100,000	$47.61	$4,761,000.00
5/23/2013	Beatrice J Cazala	EVP	Sell	96,000	$46.99	$4,511,040.00
5/23/2013	Giovanni Caforio	Insider	Sell	26,647	$46.29	$1,233,489.63
5/17/2013	James M Cornelius	Director	Sell	225,996	$42.99	$9,715,568.04
5/8/2013	James M Cornelius	Director	Sell	20,000	$39.85	$797,000.00
5/2/2013	James M Cornelius	Director	Sell	20,000	$39.76	$795,200.00
4/11/2013	James M Cornelius	Director	Sell	20,000	$41.15	$823,000.00
3/13/2013	James M Cornelius	Director	Sell	20,000	$38.18	$763,600.00
3/13/2013	John E Elicker	SVP	Sell	3,409	$38.51	$131,280.59
2/27/2013	Giovanni Caforio	Insider	Sell	12,150	$37.08	$450,522.00
2/26/2013	James M Cornelius	Director	Sell	20,000	$36.58	$731,600.00
1/17/2013	James M Cornelius	Director	Sell	20,000	$34.33	$686,600.00
12/28/2012	James M Cornelius	Director	Sell	20,000	$32.06	$641,200.00
10/3/2012	James M Cornelius	Director	Sell	20,000	$33.71	$674,200.00
8/10/2012	James M Cornelius	Director	Sell	10,000	$31.81	$318,100.00

(Data available from 1/1/2013 forward)

Bristol-Myers Squibb (NYSE BMY) News Headlines

Source:

Date	Headline
	Bristol-Myers' Opdivo Gets Priority Review for Lung Cancer www.zacks.com - April 19 at 5:23 PM
	Bristol-Myers Squibb (BMY) PT Set at $65.00 by Cowen www.americanbankingnews.com - April 19 at 12:16 PM
	Bristol-Myers Squibb (BMY) Says FDA Accepted sBLA for Opdivo in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review www.streetinsider.com - April 19 at 8:54 AM
	I'm Buying Bristol-Myers Down Near 52-Week Lows seekingalpha.com - April 19 at 8:54 AM
	Cabometyx Could Be Exelixis’s Long-Term Growth Driver finance.yahoo.com - April 19 at 8:54 AM
	Bristol-Myers Squibb (BMY) Scheduled to Post Earnings on Thursday www.americanbankingnews.com - April 19 at 1:56 AM
	Bristol-Myers Squibb (BMY) Given Average Rating of "Hold" by Brokerages www.americanbankingnews.com - April 18 at 5:30 PM
	Bristol-Myers Squibb (BMY) Rating Increased to Strong-Buy at Vetr www.americanbankingnews.com - April 18 at 5:18 PM
	FDA OKs Bristol-Myers' Opdivo + Yervoy for first-line kidney cancer seekingalpha.com - April 18 at 5:10 PM
	U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review finance.yahoo.com - April 18 at 5:10 PM
	Trader adding to this beaten pharma stock finance.yahoo.com - April 18 at 5:10 PM
	Bristol-Myers Squibb (BMY) Price Target Lowered to $47.00 at BMO Capital Markets www.americanbankingnews.com - April 18 at 10:38 AM
	Bristol-Myers Squibb (BMY) Given a $58.00 Price Target by Credit Suisse Group Analysts www.americanbankingnews.com - April 18 at 8:41 AM
	FY2018 Earnings Forecast for Bristol-Myers Squibb (BMY) Issued By William Blair www.americanbankingnews.com - April 18 at 8:38 AM
	Q1 2018 Earnings Estimate for Bristol-Myers Squibb (BMY) Issued By SunTrust Banks www.americanbankingnews.com - April 18 at 7:58 AM
	Calculating The Intrinsic Value Of Bristol-Myers Squibb Company (NYSE:BMY) finance.yahoo.com - April 17 at 5:21 PM
	Bristol-Myers (BMY) Down as Merck NSCLC Study Fares Better www.msn.com - April 17 at 5:21 PM
	Bristol-Myers Squibb (BMY) Price Target Lowered to $61.00 at Bank of America www.americanbankingnews.com - April 17 at 3:03 PM
	Bristol-Myers Squibb (BMY) Rating Reiterated by William Blair www.americanbankingnews.com - April 17 at 9:19 AM
	BRIEF-Bristol-Myers Squibb Collaborates With Janssen To Develop & Commercialize Factor XIa Inhibitors www.reuters.com - April 17 at 8:37 AM
	Why Bristol-Myers Squibb is making a big bet its approach to treating lung cancer is the right one www.businessinsider.com - April 17 at 8:37 AM
	Pfizer Reportedly Rules Out Bristol-Myers Squibb Deal -- Here Are 3 Better Acquisition Targets www.msn.com - April 17 at 8:37 AM
	Morgan Stanley Downgrades Bristol-Myers Squibb (BMY) to Hold www.americanbankingnews.com - April 17 at 8:11 AM
	$5.10 Billion in Sales Expected for Bristol-Myers Squibb (BMY) This Quarter www.americanbankingnews.com - April 17 at 4:59 AM
	Bristol-Myers teams up with J&J to develop next-gen cardiovascular therapy seekingalpha.com - April 16 at 5:20 PM
	Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo www.msn.com - April 16 at 5:20 PM
	BRIEF-Bristol-Myers Squibb Says Cancer Drug Combo Reduces Death Risk By 42 Pct www.reuters.com - April 16 at 5:20 PM
	Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy finance.yahoo.com - April 16 at 5:20 PM
	Merck Cements Lead in Lung Cancer With Bristol-Myers Fizzling www.msn.com - April 16 at 5:20 PM
	Bristol-Myers Partners With Janssen on Anticlotting Therapy www.bloomberg.com - April 16 at 5:20 PM
	Global Antidiabetics Market Overview 2017-2026: Eli Lilly, Abbott Laboratories, Bristol-Myers Squibb www.marketwatch.com - April 16 at 9:17 AM
	Opdivo Plus Low-Dose Yervoy Combination Reduces the Risk of Progression or Death by 42% Versus Chemotherapy in First-Line Lung Cancer Patients with High Tumor Mutational Burden (TMB) finance.yahoo.com - April 16 at 9:17 AM
	Bristol-Myers Squibb to Post Q1 2018 Earnings of $0.85 Per Share, Jefferies Group Forecasts (BMY) www.americanbankingnews.com - April 16 at 1:44 AM
	Bristol-Myers Squibb (BMY) Raised to Strong-Buy at Vetr www.americanbankingnews.com - April 15 at 8:22 PM
	Zacks: Brokerages Expect Bristol-Myers Squibb (BMY) Will Post Earnings of $0.84 Per Share www.americanbankingnews.com - April 15 at 3:11 AM
	Bristol-Myers Squibb (BMY) Rating Lowered to Sell at BidaskClub www.americanbankingnews.com - April 15 at 12:05 AM
	Bristol-Myers teams up with Illumina to develop companion diagnostics for cancer immunotherapies seekingalpha.com - April 13 at 5:18 PM
	BRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies www.reuters.com - April 13 at 5:18 PM
	Bristol-Myers' Opdivo extends survival in late-stage lung study in Chinese population seekingalpha.com - April 13 at 5:18 PM
	Bristol-Myers Collaborates With Harvard Fibrosis Network finance.yahoo.com - April 13 at 5:18 PM
	Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly Chinese Population with Previously Treated Non-Small Cell Lung Cancer (NSCLC) finance.yahoo.com - April 13 at 5:18 PM
	Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibb’s Oncology Immunotherapies finance.yahoo.com - April 13 at 5:18 PM
	Illumina shares advance on Bristol-Myers cancer drug collaboration finance.yahoo.com - April 13 at 5:18 PM
	Bristol-Myers Squibb (BMY) Given a $66.00 Price Target at Jefferies Group www.americanbankingnews.com - April 13 at 10:13 AM
	Global Acute lymphocytic/lymphoblastic leukemia therapeutics Market Overview 2017-2026: Amgen, Bristol- Myers Squibb www.marketwatch.com - April 13 at 8:46 AM
	Global Antidiabetic Sulphonylureas Market Overview 2017-2026: Novo Nordisk, Bristol-Myers Squibb www.marketwatch.com - April 13 at 8:46 AM
	Around Town N'at: Pressley Ridge, MDA, Carlow University and Bristol-Myers Squibb www.bizjournals.com - April 13 at 8:46 AM
	Drugmakers vie for dominance in lung cancer treatment finance.yahoo.com - April 13 at 8:46 AM
	Pfizer's Deal Potential Doesn't Stop at Bristol-Myers www.bloomberg.com - April 12 at 5:19 PM
	Bristol-Myers Squibb Enters Oversold Territory www.nasdaq.com - April 12 at 5:19 PM

Bristol-Myers Squibb (NYSE:BMY) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Bristol-Myers Squibb (NYSE:BMY) Income Statement, Balance Sheet and Cash Flow Statement

Bristol-Myers Squibb (NYSE BMY) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff